Article
Oncology
Ling Peng, Wen-Hua Liang, De-Guang Mu, Song Xu, Shao-Dong Hong, Justin Stebbing, Fei Liang, Yang Xia
Summary: For PD-L1 negative NSCLC patients, nivolumab plus chemotherapy in combination with angiogenesis inhibition or anti-CTLA-4 therapy showed the greatest benefits among first-line treatment strategies based on Bayesian network meta-analysis. This personalized treatment approach may improve outcomes for patients, but individual safety considerations should be taken into account. Further validation is needed to confirm these findings.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Lingling Li, Chenghui Pi, Xin Yan, Jiangyue Lu, Xuhui Yang, Chunyu Wang, Xiaoyan Li, Sujie Zhang, Zhibo Zhang, Yi Sun, Yi Hu
Summary: This study showed that pretreatment LIPI can serve as a prognostic biomarker for advanced small cell lung cancer patients receiving first-line PD-1/PD-L1 inhibitors plus chemotherapy, with patients in the LIPI good group demonstrating better survival outcomes.
FRONTIERS IN ONCOLOGY
(2021)
Review
Immunology
Jianqiong Yin, Yuanjun Wu, Xue Yang, Lu Gan, Jianxin Xue
Summary: Immune checkpoint inhibitors (ICIs) are drugs used to treat non-small-cell lung cancer by enhancing the function of T cells and producing long-lasting antitumor effects. However, ICIs can cause immune-related adverse events (irAEs), including severe pneumonia. Currently, the diagnosis and mechanisms of checkpoint inhibitor pneumonitis (CIP) are not well understood.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Mingfeng He, Taihao Zheng, Xiaoyue Zhang, Yuan Peng, Xuan Jiang, Yusheng Huang, Benxu Tan, Zhenzhou Yang
Summary: The study suggests that chemotherapy plus ICIs may improve PFS and ORR compared to single-agent ICIs for advanced NSCLC patients with PD-L1 >= 50%, but does not lead to OS benefit.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Review
Oncology
Xiao Hu, Jin Ren, Qianfei Xue, Rumei Luan, Dongyan Ding, Jie Tan, Xin Su, Junling Yang
Summary: Immune checkpoint inhibitors have a significant role in the treatment of non-small cell lung cancer. However, immune-related adverse events, particularly checkpoint inhibitor pneumonitis, limit their clinical application. This study summarizes the occurrence, characteristics, pathogenesis, risk factors, and management of checkpoint inhibitor pneumonitis to enhance our understanding and guide treatment.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2023)
Review
Immunology
Qian Li, Jingjing Han, Yonglin Yang, Yu Chen
Summary: Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide. In recent years, immunotherapy using immune checkpoint inhibitors, particularly targeting the PD-1/PD-L1 axis, has brought fundamental changes to the treatment of advanced HCC. However, challenges remain and combination therapy may be a better option to improve the low remission rate.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Jianing Chen, Yaokai Wen, Xiangling Chu, Yuzhi Liu, Chunxia Su
Summary: This study revealed the unique adverse event profile of NSCLC patients with hypertension receiving anti-PD-1/PD-L1 inhibitors, showing that patients with hypertension were more prone to reporting interstitial lung disease when undergoing anti-PD-1 treatment.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Lingling Li, Zhibo Zhang, Yi Hu
Summary: The study suggests that in advanced SCLC patients receiving first-line ICIs treatment, changes in NSE levels can serve as an important prognostic tool, with normal NSE levels associated with better survival outcomes.
Article
Oncology
Jinzhao Zhai, Jiangyue Lu, Zhibo Zhang, Yuan Wang, Xiaoyan Li, Sujie Zhang, Shuai Mu, Xiaoyu Zhi, Xiangwei Ge, Di Lu, Yi Hu, Jinliang Wang
Summary: This study compared the efficacy of immune checkpoint inhibitor (ICI) plus chemotherapy and bevacizumab plus chemotherapy in the first-line treatment of non-squamous non-small cell lung cancer. The results showed that ICI-chemotherapy was associated with better overall survival compared to Bev-chemotherapy, while there were no differences in progression-free survival, overall response rate, and grade >= 3 treatment-related adverse events between the two treatments.
Article
Medicine, General & Internal
Jung Han Kim, Soo Young Jeong, Jae-Jun Lee, Sung Taek Park, Hyeong Su Kim
Summary: The study conducted a Bayesian network meta-analysis to suggest frontline treatments for advanced NSCLC with high PD-L1 expression, and found that ICI plus chemotherapy with/without bevacizumab might be the best options in terms of overall survival.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Oncology
Ofek Mussafi, Jie Mei, Wenjun Mao, Yuan Wan
Summary: This review summarizes the use of other promising immunotherapies and targeted therapies in combination with immune checkpoint inhibitors (ICI) in the treatment of lung cancers and briefly discusses possible outlooks for future treatment.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Ewa Surmiak, Katarzyna Magiera-Mularz, Bogdan Musielak, Damian Muszak, Justyna Kocik-Krol, Radoslaw Kitel, Jacek Plewka, Tad A. Holak, Lukasz Skalniak
Summary: This article compares representative molecules from different classes in terms of their PD-1/PD-L1 dissociation capacity and in vitro bioactivity. Recent discoveries underscore important differences in the mechanisms of action of these molecules, with one principal feature to consider being the eventual human PD-L1 specificity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Wei Chen, Jiayi Chen, Lin Zhang, Sheng Cheng, Junxian Yu
Summary: This study compared the efficacy of different immunotherapy regimens in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression >= 50%. The results showed that pembrolizumab plus chemotherapy had the best overall survival, while tislelizumab plus chemotherapy and sintilimab plus chemotherapy had the best progression-free survival.
Article
Oncology
Arielle Elkrief, Joao M. Victor Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R. Preeshagul, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe Lamberti, Jacklynn Egger, Jamie E. Chaft, Charles M. Rudin, Gregory J. Riely, Mark G. Kris, Marc Ladanyi, Yuan Chen, Matthew D. Hellmann, Ronglai Shen, Mark M. Awad, Adam J. Schoenfeld
Summary: This study compared the first-line efficacy of single-agent immunotherapy to chemotherapy combined with immunotherapy in patients with advanced lung adenocarcinoma. The results showed that chemotherapy combined with immunotherapy improved the objective response rate and progression-free survival in patients with tumor PD-L1 expression ≥1%. Among patients with PD-L1 expression ≥50%, never-smokers derived a better survival benefit from chemotherapy combined with immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Jin Yang, Ran Zeng, Jianping Zhou, Lifeng Luo, Mengchen Lyu, Fang Liu, Xianwen Sun, Ling Zhou, Xiaofei Wang, Zhiyao Bao, Wei Chen, Daphne W. Dumoulin, Beili Gao, Yi Xiang
Summary: This study aimed to explore the efficacy, prognosis, and safety of patients with advanced lung cancer who received immune checkpoint inhibitor rechallenge. The findings suggest that rechallenge may be an attractive option for patients who discontinued treatment due to immune-related adverse events, but further research is needed for patients with disease progression.
TRANSLATIONAL LUNG CANCER RESEARCH
(2022)
Article
Oncology
Masashi Nishimura, Yoshifumi Kimizuka, Takunori Ogawa, Motohiro Tsuchiya, Yoshiki Kato, Akira Matsukida, Shunya Igarashi, Koki Ito, Yusuke Serizawa, Tomomi Tanigaki, Yuji Fujikura, Yuka Katsurada, Sho Ogata, Akihiko Kawana
Summary: This study reports a case of IgG4-related retroperitoneal fibrosis occurring after chemotherapy. The patient showed improvement after discontinuing immunotherapy and receiving steroid treatment.
Article
Oncology
Yuta Ohishi, Yoko Nakanishi, Yukari Hirotani, Atsuko Suzuki, Tomoyuki Tanino, Haruna Nishimaki-Watanabe, Hiroko Kobayashi, Fumi Nozaki, Sumie Ohni, Xiaoyan Tang, Kentaro Hayashi, Yoshiko Nakagawa, Tetsuo Shimizu, Ichiro Tsujino, Noriaki Takahashi, Yasuhiro Gon, Shinobu Masuda
Summary: This study aimed to investigate the clinicopathological differences and therapeutic response of NSCLC patients with SDC4::ROS1 fusion to crizotinib. The study found that different ROS1 fusion partners may affect the efficacy of crizotinib and patient prognosis. In addition, higher expression levels of ROS1 and pERK1/2 in tumor cells of case 2 may be related to the therapeutic response and prognosis.
Review
Oncology
Zitong Zheng, Juanjuan Liu, Junling Ma, Runting Kang, Zhen Liu, Jiangyong Yu
Summary: Small cell lung cancer (SCLC) is a highly aggressive malignancy with limited treatment options. Over the past decade, immunotherapy has made progress in the treatment of SCLC, but current immune checkpoint inhibitors have limited benefits for patient survival. Therefore, it is important to explore new targets and develop drugs with novel mechanisms for immunotherapy in SCLC.
Article
Oncology
Kazuto Sugai, Kojiro Nakaoka, Rika Tobita, Shinji Kikuchi, Kei Inoue, Midori Enokido, Moriyuki Kiyoshima
Summary: This article presents a case of multilocular mediastinal cyst leading to the development of thymic cancer. Resection of multilocular anterior mediastinal cysts should be considered due to the challenges in preoperative diagnosis, the potential for coexisting tumors with cysts, and the risk of malignant tumor development.